(MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118010
Author :
Publish date : 2025-10-17 20:54:00
Copyright for syndicated content belongs to the linked Source.
